DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...

Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...

Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something important about this glucose monitoring specialist? DexCom shares last closed ...

Good morning, everyone. I'm Robbie Marcus, the med tech analyst at JPMorgan. Thanks for joining us at the first session to kick off the 2026 JPMorgan Healthcare Conference. I'll give a warm welcome to ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2025 with total revenue of approximately $1.260 billion, an increase of 13% over the ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems. Valued at $27.4 billion by market ...

In general, as someone without diabetes, you want your fasting blood sugar (when you haven’t eaten for at least eight hours) to be below 100 mg/dL. You want your spikes to be below 180 mg/dL, to lower ...

We might earn a commission if you make a purchase through one of the links. The McClatchy Commerce Content team, which is independent from our newsroom, oversees this content. Choosing the right CPA ...

DexCom stock rose sharply Monday after the maker of glucose monitors reported better-than-expected preliminary results for the fourth quarter.